NTRK1 and colorectal cancer: Regorafenib, targeting VEGFR1-3, KIT, PDGFR-α/β, FGFR1,2, TIE2, discoidin domain receptor tyrosine kinase 2 (DDR2), tropomyosin receptor kinase A (TRKA), Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, Abelson tyrosine kinase 1 (ABL), for gastrointestinal stromal and colorectal cancers and hepatocellular carcinoma.